Tag:

Johnson & Johnson

Latest Headlines

Latest Headlines

DexCom profitable for the first time, completes FDA submission for smartphone glucose monitor

Continuous glucose monitor company DexCom turned a profit for the first time during the fourth quarter of last year. It also said it completed its FDA submission for its first direct-access smartphone CGM, the G5, which transmits data directly to a smartphone and from the phone to a secure system.

SC's top court backs Risperdal verdict against J&J, but cuts penalty to $136M

It's bad news and good news for Johnson & Johnson's legal department today. South Carolina's Supreme Court upheld a jury verdict against the company in a Risperdal marketing lawsuit, but did slash the $327 million judgment by more than half.

Hospira and Celltrion hit a speed bump in their biosimilar dash

The FDA wants some more time to review Hospira and partner Celltrion's copy of Johnson & Johnson's blockbuster autoimmune drug Remicade, possibly delaying the drug's march onto the U.S. market.

Deal-weighing Pharmacyclics could draw $18B from J&J, Novartis: Bloomberg

So far, the 2014 pharma deal blitz has continued right on into 2015. And cancer drugmaker Pharmacyclics could be the next company to keep it going.

J&J loses first court battle over Risperdal's breast-growth side effects

The jury has spoken in Johnson & Johnson's Risperdal trial, and the news wasn't good for the U.S.-based drugmaker. The Philadelphia panel decided J&J had failed to properly warn that the antipsychotic drug could trigger breast development in boys and young men, in the first of more than 1,000 similar cases pending.

Hospira and Celltrion storm the EU with biosimilars of J&J's Remicade

Partners Hospira and Celltrion are marching forward with copies of Johnson & Johnson's blockbuster autoimmune drug Remicade, bulldozing into Europe with products expected to disrupt a multibillion-dollar market.

J&J adds $420M to legal stockpile to resolve all-metal hip implant suits

Johnson & Johnson is shelling out as much as $420 million to resolve claims over recalled hip implants, adding to its previous $2.5 billion settlement and laying more lawsuits in its ongoing courtroom battle to rest.

UPDATED: NIH funds studies of J&J's and GSK's injectable HIV meds, says daily pills lead to noncompliance

In bid to improve patient adherence, the U.S. National Institutes of Health is funding and helping run two clinical trials of long-acting injectable HIV candidates being developed by Johnson & Johnson's Janssen and GlaxoSmithKline.

J&J awaits jury verdict over Risperdal patient's breast development

Did Johnson & Johnson hide Risperdal's potential to trigger breast growth in boys? Or did the drugmaker adequately disclose the potential side effect? A Philadelphia jury is literally out deliberating on these two questions.

J&J readies to rid itself of Cordis--for as much as $2B to Cardinal Health

A deal that was rumored this summer now looks like it's ready to come to pass. Johnson & Johnson is ready to sell off its Cordis business to Cardinal Health for as much as $2 billion, according to report by Bloomberg. Cordis has elicited multiple offers from bidders, some of whom may still be in the running.